logo
Qatar announces healthcare strategy to reduce illness, extend lives and boost wellbeing

Qatar announces healthcare strategy to reduce illness, extend lives and boost wellbeing

Qatar has announced a new healthcare strategy as it looks to extend lives, reduce illnesses and enhance wellbeing of citizens and residents.
Under the theme 'Health for All,' Qatar is moving toward 2030 with a firm commitment to providing excellent and comprehensive healthcare to all residents.
This marks a new phase in the journey toward realising Qatar National Vision 2030 and the Third National Development Strategy (2024-2030), aimed at ensuring long, healthy lives for current and future generations.
Qatar healthcare strategy
By the end of 2024, all public health sector institutions, including the Ministry of Public Health, Hamad Medical Corporation, and the Primary Health Care Corporation, launched their respective health strategies for 2024-2030.
These strategies aim to meet the healthcare needs of the population according to the highest standards, while also achieving excellence and ensuring that Qatar enjoys the highest possible quality of life.
Through its Third National Health Strategy, Qatar is working to achieve several key healthcare goals, including:
Increasing life expectancy to 82.6 years
Reducing mortality from non-communicable diseases by 36 per cent
Lowering the infant mortality rate to 2 per 1,000 live births
Increasing the proportion of people engaging in at least 150 minutes of physical activity per week
Director of Strategic Planning and Performance Department at the Ministry of Public Health Huda Amer Al Katheeri said Qatar continues to develop its healthcare sector and promote the health and well-being of its population through the National Health Strategy 2024-2030.
This ambitious vision aims to build a comprehensive healthcare system that keeps pace with the latest developments and is founded on clinical excellence, sustainability, and innovation, she said.
Qatar's National Health Strategy 2024-2030 aims to improve individuals' health and ensure a longer and higher quality of life by focusing on the physical, psychological, and social aspects of health.
It is dedicated to creating an environment where the entire community participates in achieving health and well-being goals, enhancing both preventive and therapeutic interventions to reduce the spread of diseases and improve the quality of healthcare.
Al Katheeri pointed out that the strategy relies on an integrated approach aimed at achieving the highest clinical standards while ensuring the sustainability of financial and environmental resources for future generations.
The strategy's goals also include increasing local research and development, adopting innovative solutions, reducing non-communicable diseases, standardizing patient pathways, fully digitising the healthcare system, and focusing on transition centres.
These centres are a pivotal element in the healthcare system, working to rehabilitate patients and assist them in transitioning from hospital care to home or community care.
This approach enhances the role of rehabilitation services, contributing to improving the quality of life for patients and accelerating their recovery.
The Director of Strategic Planning and Performance Department at the Ministry of Public Health explained that the ambitions of the National Health Strategy are reflected in a set of priorities that aim to achieve a radical transformation in the healthcare system.
Efforts will be made to raise health awareness, empower individuals to adopt healthier lifestyles, and promote disease prevention and early detection.
The state also seeks to promote the concept of 'Health in All Policies' by integrating public health into various national policies to ensure integration across different sectors, which will positively impact the health of the community.
In terms of healthcare services, the strategy aims to achieve excellence in providing care and improving the patient experience by developing integrated care models that encompass all stages of treatment, from prevention, treatment and rehabilitation, all the way to community and extended care.
Improving the quality of primary and community care, while expanding the range of services offered in hospitals and specialised centres to ensure that all residents have access to advanced healthcare services that meet their needs efficiently and promptly, will be prioritised as well.
As part of its efforts to enhance the resilience and sustainability of the Qatar healthcare system, the strategy places special emphasis on developing governance systems and enhancing transparency in managing the healthcare sector.
It also adopts a health-financing model that ensures the sustainability of the services provided. The upcoming phase will witness a broad digital transformation in the healthcare sector, where digital solutions will be implemented to introduce new models of healthcare, enhance the patient experience, and maximise operational efficiency.
Additionally, there will be a focus on developing a unified database to support evidence-based decision-making and precise analyses in healthcare.
Al Katheeri said that the strategy prioritises research and development by enhancing the medical research environment, encouraging innovation in the healthcare sector, and providing the necessary infrastructure to support national and international cadres in this field.
The state will also work to improve the healthcare workforce by attracting the best medical talent and ensuring the optimal distribution of human resources, thus enhancing the efficiency of the healthcare system as a whole. The strategy prioritizes preparedness and effective response to health emergencies.
It will work to develop early warning systems and enhance the health sector's ability to respond to health crises efficiently and quickly, ensuring community protection and mitigating the impacts of epidemics and health disasters.
Al Katheeri also noted that the National Health Strategy includes 53 key initiatives covering different themes, such as promoting health literacy, expanding screening and early detection programs, and improving long-term care services, in addition to focusing on different population groups such as children, adolescents, the elderly, people with special needs, and workers.
Initiatives also include developing health governance systems, supporting research and innovation, strengthening public-private partnerships, and investing in biotechnology as a pillar of a sustainable health future.
The Qatar National Health Strategy 2024-2030 represents a pivotal step toward achieving a more integrated and resilient healthcare system that enhances the health and well-being of individuals and aligns with the country's aspirations for a sustainable, healthy future.
It is an ambitious vision based on clear scientific and methodological foundations, reflecting the State of Qatar's ongoing commitment to improving the quality of healthcare and ensuring a better life for all.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mubadala Bio launched to transform life sciences in UAE and beyond
Mubadala Bio launched to transform life sciences in UAE and beyond

Al Etihad

time19-05-2025

  • Al Etihad

Mubadala Bio launched to transform life sciences in UAE and beyond

19 May 2025 11:32 ABU DHABI (WAM)Mubadala Investment Company, an Abu Dhabi sovereign investor, Monday announced the launch of Mubadala Bio, a life sciences company committed to strengthening the life sciences sector in the UAE, and advancing better health outcomes for the UAE and the launch of Mubadala Bio represents a strategic step that reflects Mubadala's commitment - to healthcare resilience, drug security, and the expansion of access to essential, high-quality therapeutics and medical devices - in order to accelerate the UAE's economic diversification and build a knowledge-based Bio's integrated portfolio includes 10 facilities across Asia, Africa, and Europe alongside 6 located within the Emirates, which together serve over 100 the facilities, which span 110,000 square metres, the cumulative annual manufacturing capacity exceeds 2.5 billion tablets and capsules, as well as 120 million IVs and injectables, all enabling the production and global distribution of more than 10,000 Bio's portfolio focuses on key therapy areas that address some of the world's most pressing health needs, and support the full continuum of care - from prevention and diagnosis to treatment, ongoing support, and complementary forging long-term strategic partnerships with global industry leaders and top-tier academic institutions, Mubadala Bio is accelerating biopharma innovation and local manufacturing, cultivating world-class talent and driving accelerated advancements. This holistic strategy spans the full continuum of care by providing integrated disease solutions across prevention, diagnostics, treatment, supportive treatment, and complementary Bakheet Al Katheeri, Chief Executive Officer of Mubadala's UAE Investments Platform, said, "By launching Mubadala Bio, we are taking a transformative step towards strengthening national drug security and fostering innovation in life sciences. This positions Mubadala at the forefront of the industry, enabling us to drive long-term economic growth, build a resilient life sciences ecosystem, and elevate Abu Dhabi's role in delivering impactful health solutions on a global scale.""Through our National Champions, we continue our efforts to accelerate the UAE's economic diversification by investing in priority sectors and support building a knowledge-based economy," Al Katheeri Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, stated that the launch of Mubadala Bio marks a major milestone in the UAE's journey toward global leadership in the life sciences indsutry. He noted that the strategic focus will strengthen local capabilities in development, manufacturing, logistics, and distribution across the supply chain. Focusing on integrated biopharma and pharma logistics, Mubadala Bio aims to support the UAE's Centennial 2071 vision. As part of its launch, it will mark its first physical presence at the Make it in the Emirates 2025, showcasing the UAE's success in building a competitive life sciences industry, and reinforcing its position as a hub for innovation and local manufacturing.

Qatar: QFZ and BIOCAD sign MoU to establish biotechnology and pharmaceuticals activities
Qatar: QFZ and BIOCAD sign MoU to establish biotechnology and pharmaceuticals activities

Zawya

time18-04-2025

  • Zawya

Qatar: QFZ and BIOCAD sign MoU to establish biotechnology and pharmaceuticals activities

DOHA: Qatar Free Zones Authority (QFZ) and BIOCAD– one of Russia's leading biotechnology companies – yesterday signed a landmark Memorandum of Understanding, paving the way for the establishment of biotechnology and pharmaceuticals activities in the Free Zones in the State of Qatar, including but not limited to research and development and manufacturing processes. The MoU signing was witnessed by H E Sheikh Faisal bin Thani bin Faisal Al-Thani, Minister of Commerce and Industry – State of Qatar and Chairman of Qatar Free Zones Authority (QFZ), and H E Maxim Reshetnikov, Minister of Economic Development of the Russian Federation. The MoU was signed by H E Sheikh Mohammed bin Hamad Bin Faisal Al-Thani, CEO of Qatar Free Zones Authority (QFZ), and Dmitrii Sivokoz, CEO of BIOCAD, during the Qatar – Russia Business Forum. High-ranking officials from both countries attended the signing ceremony, alongside distinguished industry leaders and guests. The MoU seeks to create conditions for cooperation in strategic areas such as new technologies, logistics and biomedical sciences. BIOCAD shall also encourage its partners and suppliers to establish presence in Qatar's Free Zones as part of broadening Qatar's biomedical sciences ecosystem. In addition, BIOCAD shall support local research and development and engage with leading Qatari universities and research institutions, fostering academic-industry partnerships and involving the local scientific community in collaborative R&D initiatives. Sheikh Mohammed bin Hamad bin Faisal Al-Thani, CEO of QFZ, commented on the occasion: 'Our partnership with BIOCAD is a strategic step in positioning Qatar as a hub for biomedical innovation. It reflects QFZ's commitment to attracting future-focused industries and advancing the goals of the Third National Development Strategy and Qatar National Vision 2030.' Recently, a delegation from the Qatari Ministry of Public Health paid a visit to the Russian Federation, with a special focus on BIOCAD's R&D and manufacturing facilities. During the meeting, the parties discussed potential cooperation in providing Qatar's population with modern, effective, and safe medications, including pharmaceutical localization and the establishment of biotechnological production within Qatar. 'The company is interested in entering the Qatari pharmaceutical market not just as a supplier of its products, but also as a reliable state partner, contributing to the development of the country's own pharmaceutical industry through the transfer of technology for the production of biotechnological medicine for Qatar and global markets,' said Dmitry Sivokoz, CEO of BIOCAD. He added that:'this cooperation would not only improve access to high-efficacy therapies for Qatari patients but also foster the development of the local pharmaceutical industry and strengthen bilateral ties between Russia and Qatar.' © Dar Al Sharq Press, Printing and Distribution. All Rights Reserved. Provided by SyndiGate Media Inc. (

Qatar Free Zones, Russia's BIOCAD sign deal on biotech activities in Qatar
Qatar Free Zones, Russia's BIOCAD sign deal on biotech activities in Qatar

Zawya

time18-04-2025

  • Zawya

Qatar Free Zones, Russia's BIOCAD sign deal on biotech activities in Qatar

Moscow: Qatar Free Zones Authority and BIOCAD ,one of Russia's leading biotechnology companies, today signed a landmark Memorandum of Understanding, paving the way for the establishment of biotechnology and pharmaceuticals activities in the Free Zones in the State of Qatar, including but not limited to research and development and manufacturing processes. The MoU signing was witnessed by Minister of Commerce and Industry HE Sheikh Faisal bin Thani bin Faisal Al Thani, who is also Chairman of Qatar Free Zones Authority (QFZ), and HE Minister of Economic Development of the Russian Federation Maxim Reshetnikov. The MoU was signed by CEO of Qatar Free Zones Authority (QFZ) HE Sheikh Mohammed Bin Hamad Bin Faisal Al Thani and CEO of BIOCAD Dmitrii Sivokoz during the Qatar Russia Business Forum. High-ranking officials from both countries attended the signing ceremony, alongside distinguished industry leaders and guests. The MoU seeks to create conditions for cooperation in strategic areas such as new technologies, logistics and biomedical sciences. BIOCAD shall also encourage its partners and suppliers to establish presence in Qatars Free Zones as part of broadening Qatar's biomedical sciences ecosystem. In addition, BIOCAD shall support local research and development and engage with leading Qatari universities and research institutions, fostering academic-industry partnerships and involving the local scientific community in collaborative R&D initiatives. HE Sheikh Mohammed Bin Hamad Bin Faisal Al Thani, the CEO of Qatar Free Zones Authority (QFZ), commented on the occasion said that: "Our partnership with BIOCAD is a strategic step in positioning Qatar as a hub for biomedical innovation. It reflects QFZs commitment to attracting future-focused industries and advancing the goals of the Third National Development Strategy and Qatar National Vision 2030." Recently, a delegation from the Qatari Ministry of Public Health paid a visit to the Russian Federation, with a special focus on BIOCADs R&D and manufacturing facilities. During the meeting, the parties discussed potential cooperation in providing Qatar's population with modern, effective, and safe medications, including pharmaceutical localization and the establishment of biotechnological production within Qatar. "The company is interested in entering the Qatari pharmaceutical market not just as a supplier of its products, but also as a reliable state partner, contributing to the development of the country's own pharmaceutical industry through the transfer of technology for the production of biotechnological medicine for Qatar and global markets," said CEO of BIOCAD Dmitry Sivokoz. He added that: "this cooperation would not only improve access to high-efficacy therapies for Qatari patients but also foster the development of the local pharmaceutical industry and strengthen bilateral ties between Russia and Qatar." As Qatar and its Free Zones accelerate their efforts to become a globally recognized center for biomedical sciences innovation and high-tech research and development, this partnership underscores the countrys commitment to enabling advanced industries that serve both the national interest and global health outcomes. © Dar Al Sharq Press, Printing and Distribution. All Rights Reserved. Provided by SyndiGate Media Inc. (

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store